Last reviewed · How we verify
Instramuscular vaccine
At a glance
| Generic name | Instramuscular vaccine |
|---|---|
| Sponsor | Medicago |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Instramuscular vaccine CI brief — competitive landscape report
- Instramuscular vaccine updates RSS · CI watch RSS
- Medicago portfolio CI